Cure Today1h
Understanding the Benefit of Subcutaneous Versus IV Opdivo in Patients With Solid Tumors
Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for ...
The American Journal of Managed Care6d
FDA Approves First Subcutaneous Nivolumab Injection in Most Solid Tumors
FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.
Renal & Urology News1d
FDA Approves Opdivo Qvantig, a Subcutaneous Formulation of Nivolumab
The FDA has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), a new subcutaneous injection formulation of Opdivo.
Pharmaceutical Technology3d
Nivolumab biosimilar by Amgen for Metastatic Melanoma: Likelihood of Approval
Nivolumab biosimilar is under clinical development by Amgen and currently in Phase III for Metastatic Melanoma.
Targeted Oncology12d
FDA Approves Subcutaneous Nivolumab Across Existing Solid Tumor Indications
On December 27, 2024, subcutaneous nivolumab (Opdivo Qvantig) was approved by the FDA in all previously approved adult solid ...
Cancer Therapy Advisor17h
Some Young Patients With Hodgkin Lymphoma May Be Able to Avoid Transplant
Young patients with low-risk, relapsed Hodgkin lymphoma may be able to avoid transplant, data from 3 studies suggest.
FDA approves subcutaneous opdivo qvantig for most solid tumor indications
The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for ...
Targeted Oncology2h
Amezalpat Gains FDA Orphan Drug Status in HCC
The FDA granted orphan drug designation to amezalpat in hepatocellular carcinoma based on phase 1b/2 data showing efficacy ...
Monthly Prescribing Reference6d
FDA Approves Opdivo Qvantig, a Subcutaneous Formulation of Nivolumab
Opdivo Qvantig combines nivolumab, a programmed death receptor-1 (PD-1)-blocking antibody, with hyaluronidase, an endoglycosidase that increases the permeability of the SC tissue. Opdivo was ...
Pharmaceutical Technology9d
Nivolumab by Bristol-Myers Squibb for Osteosarcoma: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II drugs for Osteosarcoma have a 13% phase transition success ...
ascopubs.org26d
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047
High Omega-3, Low Omega-6 Diet With Fish Oil for Men With Prostate Cancer on Active Surveillance: The CAPFISH-3 Randomized Clinical Trial Nivolumab plus relatlimab demonstrated a statistically ...